Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2017-04-02 Capital/Financing Update
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Entitlement Offer Cleansing Statement 2 pages 96.0KB
Capital/Financing Update Classification · 95% confidence The document is a notice under section 708AA(2)(f) of the Corporations Act 2001 regarding a proposed capital raising through a non-underwritten pro-rata accelerated non-renounceable entitlement offer to raise approximately A$45 million. It details the terms of the entitlement offer, the record date, and compliance statements under the Corporations Act. The document is a formal announcement about a financing activity, specifically a capital raising event. It does not contain financial statements or detailed financial analysis but rather informs about the capital raising and its regulatory compliance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not an announcement of a report publication, so it is not RPA. Hence, the classification is CAP with high confidence.
2017-04-02 English
Opthea to Host Update on OPT-302 Phase 1/2A wAMD Trial 3 pages 266.6KB
Call Transcript Classification · 90% confidence The document is an ASX and media release dated 31 March 2017 announcing a conference call/webcast scheduled for 3 April 2017. The content focuses on an update regarding the Phase 1/2A clinical trial of OPT-302 for wet AMD. It provides details on how to access the live webcast and conference call, background information on the company and the drug, and forward-looking statements. There are no financial statements, detailed financial analysis, or comprehensive report data included. The document is primarily an announcement of a conference call event rather than the transcript or detailed presentation itself. Therefore, the document fits best as a Call Transcript (CT) category, as it relates to a conference call event, but since it is only an announcement of the call and webcast, it is not a transcript. However, given the options, the closest and most appropriate classification is Call Transcript (CT) because it is about a conference call/webcast update. Confidence is high because the document clearly announces a conference call/webcast event with clinical trial updates, which is typical for CT filings.
2017-03-30 English
Trading Halt 2 pages 277.5KB
Regulatory Filings Classification · 95% confidence The document is a market release dated 30 March 2017 from Opthea Limited requesting a trading halt on its securities pending the release of an announcement related to clinical trial results and a potential capital raising. The text is short (1970 characters) and primarily serves as a notification to the market about the trading halt, not the actual announcement or report itself. It references a future announcement but does not contain financial data or detailed report content. Therefore, it is an announcement related to capital/financing activity but is specifically a trading halt notice. Given the filing definitions, this fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance document rather than a Capital/Financing Update (CAP) which would contain substantive financing details. Hence, the classification is RNS with high confidence.
2017-03-29 English
Opthea Receives EU Regulatory Feedback for OPT-302 Program 3 pages 267.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX and media release dated 20 March 2017 from Opthea Limited. It discusses positive feedback from European regulatory agencies regarding the clinical development program of OPT-302 for wet AMD. The content focuses on clinical trial plans, regulatory advice, and drug development updates. There are no financial statements, earnings data, or detailed financial analysis. The document is a corporate announcement about regulatory and clinical progress rather than a financial report or detailed investor presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is a regulatory announcement about clinical program progress and regulatory feedback, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2017-03-19 English
Ceasing to be a substantial holder 2 pages 106.9KB
Major Shareholding Notification Classification · 95% confidence The document contains a table listing dates, entities (Packer & Co, Investigator Trust), nature of changes, and consideration amounts related to transactions. The content appears to be reporting on transactions involving shares or ownership interests, with terms like 'Onmarket sale' and 'Onmarket purchase' implied by the corrupted text. The document length is short (1452 characters) and does not contain financial statements or detailed analysis. It is not an announcement of a report but a record of transactions by significant shareholders or insiders. Given the nature of the data, this fits best with the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document is not a full report, call transcript, or management information, nor is it a regulatory filing or announcement of a report publication. Therefore, the classification is MRQ with high confidence.
2017-03-12 English
Opthea Completes FDA Meeting to Inform OPT-302 Program 3 pages 266.9KB
Capital/Financing Update Classification · 95% confidence The document is an ASX and media release dated 9 March 2017 from Opthea Limited. It discusses the completion of a Type C meeting with the FDA regarding the clinical development program and Phase 2B clinical trial of OPT-302 for wet AMD. The content focuses on regulatory guidance, clinical trial design, and company commentary on the meeting outcomes. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about regulatory and clinical development progress rather than a financial report or detailed investor presentation. It is not a report publication announcement since it contains substantive information about the FDA meeting and clinical program. The document fits best as a Capital/Financing Update (CAP) because it relates to regulatory progress impacting the company's drug development pipeline, which is material information for investors and capital markets. Therefore, the classification is CAP with high confidence.
2017-03-08 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.